GlassScriptPhysician profile
Michael J Hong
NPI 1760595771
$8,561.70
in general payments reported to CMS, 2019-2025
48 companies · $1,299 in 2025
The $1,299 reported for 2025 was more than what 76% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,641 · 2020: $462 · 2021: $1,034 · 2022: $1,059 · 2023: $1,464 · 2024: $1,602 · 2025: $1,299.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,344 · Education: $21.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,344.10 |
| Education | $21.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,220.35 | 2019-2025 | |
| Amgen INC. | $888.30 | 2019-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $727.43 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $691.25 | 2021-2025 | Verquvo, Winrevair, Capvaxive |
| Pfizer INC. | $611.32 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $446.63 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $332.93 | 2019-2025 | Camzyos, Eliquis |
| Novo Nordisk INC | $301.17 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $266.42 | 2021-2024 | |
| Biotronik INC. | $250.97 | 2019-2022 | |
| Boston Scientific Corporation | $247.21 | 2020-2025 | Watchman Flx, Lux-Dx Insertable Cardiac Monitor, Emblem Mri S-Icd |
| Scpharmaceuticals INC. | $191.78 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $159.23 | 2019-2023 | |
| Genzyme Corporation | $156.45 | 2019-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $142.21 | 2019-2024 | Lifevest |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $139.03 | 2024-2025 | Impella |
| Gilead Sciences, INC. | $138.79 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $134.81 | 2024 | Arcalyst |
| Abbott Laboratories | $127.72 | 2019-2025 | Aveir |
| Baxter Healthcare | $123.71 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Astrazeneca Pharmaceuticals LP | $116.09 | 2019-2025 | Farxiga |
| Actelion Pharmaceuticals US, INC. | $112.05 | 2023-2025 | Opsumit, Uptravi |
| Impulse Dynamics (USA) INC. | $89.78 | 2023 | Optimizer |
| Edwards Lifesciences Corporation | $87.92 | 2023-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Amarin Pharma, INC. | $87.24 | 2019-2021 | |
| Alnylam Pharmaceuticals INC. | $80.88 | 2023-2025 | Onpattro |
| Cvrx, INC. | $76.36 | 2025 | Barostim Neo System |
| Medtronic, INC. | $75.29 | 2021-2025 | Progrip |
| Vifor Pharma, INC. | $64.79 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $64.62 | 2019-2024 | Evkeeza |
| Kiniksa Pharmaceuticals, LTD. | $63.42 | 2023 | Arcalyst |
| Lantheus Medical Imaging, INC. | $53.39 | 2019-2020 | |
| Medtronic Vascular, INC. | $44.52 | 2019-2020 | |
| Astellas Pharma US INC | $34.61 | 2020 | |
| Daiichi Sankyo INC. | $29.64 | 2019-2020 | |
| Esperion Therapeutics, INC. | $29.22 | 2021-2024 | Nexletol |
| Irhythm Technologies, INC. | $25.97 | 2021 | |
| Terumo Medical Corporation | $25.35 | 2022 | |
| Xeris Pharmaceuticals, INC. | $24.19 | 2023 | Keveyis |
| Inspire Medical Systems, INC. | $22.85 | 2025 | Inspire |
| Bridgebio Pharma, INC. | $22.26 | 2025 | Attruby |
| Kestra Medical Technology Services, INC. | $19.60 | 2022 | |
| Philips North America LLC | $13.95 | 2019 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Hong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.